Search Results
Found 3 results
510(k) Data Aggregation
(188 days)
The Cozart® EIA Amphetamines Oral Fluid Microplate Kit is intended for use in clinical and forensic laboratories when used in conjunction with the Cozart® RapiScan Oral Fluid collection system. Using this collection system it provides qualitative screening results for amphetamines in human oral fluid at a cutoff concentration of 15ng/ml. This is equal to 45ng/ml in neat oral fluid as the collection system involves a 1:3 dilution of the sample.
This assay is for professional use only and provides only a preliminary analytical test result. Clinical consideration and professional judgement must be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. In order to obtain a more confirmed analytical result a more specific alternative chemical method is needed. Gas Chromatography/Mass Spectrometry (GCMS) is the preferred confirmatory method.
The Cozart® EIA Amphetamines Oral Fluid Microplate Kit is a laboratory based test for the detection of amphetamines in human oral fluid using a cutoff equivalent to 45ng/mL. The device detailed above was compared to Gas Chromatography/Mass Spectrometry (GC/MS).
As can be seen from the Principle of the Test section in the pack insert, the Cozart® EIA Amphetamines Oral Fluid Microplate Kit is a competitive ELISA for the detection of amphetamines in human oral fluid.
The Cozart® EIA Amphetamines Oral Fluid Microplate kit supplies the following reagents - a microtitre plate coated with antibody, enzyme conjugate reagent, wash buffer, substrate solution, stop solution and four calibrators (0, 2, 15 and 50ng/ml amphetamine in oral fluid matrix).
Here's an analysis of the provided text, outlining the acceptance criteria and the study data, as requested:
Acceptance Criteria and Device Performance Study for Cozart® EIA Amphetamines Oral Fluid Microplate Kit
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are not explicitly stated as distinct thresholds in the provided document. Instead, the document presents comparison data against a "gold standard" (GC/MS) and a predicate device. Based on the performance reported, an implicit acceptance criterion can be inferred as achieving a high agreement with GC/MS. The precision (CV%) is explicitly stated as acceptable if below 10%.
| Parameter | Acceptance Criteria (Inferred/Explicit) | Reported Device Performance (Cozart® EIA Amphetamines Oral Fluid Microplate Kit) |
|---|---|---|
| Overall Agreement with GC/MS | High agreement with GC/MS (e.g., comparable to or better than predicate) | 96% |
| Precision (CV%) | < 10% (for qualitative manual ELISA assay) | 2.7-12.4% (total precision <13%) for the kit; <11% for precision study |
| Sensitivity | Sufficiently low to detect amphetamines at specified cutoff (45ng/ml or 15ng/ml diluted) | 1.2 ng/mL |
| Specificity (Cross-reactivity) | No cross-reactivity with common interferents; well-defined cross-reactivity with related compounds | 20 potential interferents tested - none cross-reacted. 7 of 11 related compounds showed cross-reactivity. |
| Cutoff Concentration Validation | Samples at -50% and +50% of cutoff are correctly classified. | 7.5ng/ml absorbances higher than 15ng/ml calibrator; 22.5ng/ml absorbances lower than 15ng/ml calibrator. |
| Interference | No interference from common oral fluid components/ingestions. | No interference observed from various parameters (alcohol, smoking, coffee, food, etc.). |
| Stopped Assay Stability | Absorbance readable within a specific timeframe. | Must be read within 15 minutes at 450nm. |
| Assay Drift | Limited change in results across sample addition times. | Sample addition must take place within 25 minutes. |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Test Set: 163 samples.
- Data Provenance: Not explicitly stated regarding country of origin or whether the data was retrospective or prospective. However, the context suggests these were human oral fluid samples collected for "clinical and forensic samples" for the purpose of this study.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
Not applicable. The ground truth was established by Gas Chromatography/Mass Spectrometry (GC/MS), which is an analytical chemical method, not human expert consensus for this type of test.
4. Adjudication Method for the Test Set
Not applicable, as the ground truth was established by GC/MS, an objective chemical analysis method, not by human experts requiring adjudication.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This device is an immunoassay (ELISA) for detecting amphetamines. It is a laboratory-based automated or semi-automated test, not a medical imaging or diagnostic device requiring human reader interpretation, nor does it involve AI assistance in the context of human reader improvement.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done
Yes, the performance study describes the standalone performance of the Cozart® EIA Amphetamines Oral Fluid Microplate Kit. The device (kit) was tested independently, and its results were compared directly against GC/MS. There is no human-in-the-loop component mentioned that would alter the device's output.
7. The Type of Ground Truth Used
The ground truth used was Gas Chromatography/Mass Spectrometry (GC/MS). The document explicitly states: "Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method." and "The Cozart® EIA Amphetamines Oral Fluid Microplate Kit was compared to Gas Chromatography/Mass Spectrometry (GC/MS)."
8. The Sample Size for the Training Set
The document does not provide information about a separate "training set" or its size. The 163 samples described were used for the performance comparison study, which assesses the device's accuracy against the ground truth. As this is an immunoassay kit, not a machine learning algorithm that typically requires a large training set, the concept of a training set in this context is less relevant in the same way it would be for AI/ML device submissions. The kit would have been developed and optimized through internal R&D, but specific training set data is not typically disclosed in 510(k) summaries for such devices.
9. How the Ground Truth for the Training Set Was Established
As no "training set" is explicitly mentioned for the reported comparison study (see #8), this question is not directly applicable. If a training set were implied for the kit's development, its ground truth would also presumably be established by highly accurate confirmatory methods like GC/MS.
Ask a specific question about this device
(111 days)
The ID Power Infuser™ is intended to support primary intravenous fluid resuscitation therapy to rapidly restore intravascular volume and blood pressure in patients with clinical shock, hypotension, and hypoperfusion states as a result of hemorrhagic blood loss, occult hemorrhage, neurogenic shock, and septic shock.
The device is intended to be used by medical, paramedical, and EMT personnel in the field, and in pre-hospital and hospital environments.
The ID Power Infuser™ is intended to deliver crystalloid and colloid resuscitative fluids only. It is NOT intended to support the infusion of blood or blood products, nor is it intended for the delivery of any pharmaceutical or other medications.
Not Found
The provided text describes a 510(k) premarket notification for a device named "ID Power Infuser™." However, the document is a regulatory approval letter and an 'Indications For Use Statement'. It does not contain any information about acceptance criteria, device performance studies, sample sizes, ground truth establishment, or expert involvement for the ID Power Infuser™.
Therefore, I cannot provide the requested information. The document focuses on regulatory approval based on substantial equivalence to a predicate device, rather than detailed performance study results against specific acceptance criteria.
Ask a specific question about this device
(21 days)
The Medical Solutions, Inc.'s Reusable Pressure Infusor is a device consisting of an inflatable cuff which is placed around an I.V. bag. When the device is inflated, it increases the pressure on the I.V. bag to assist the infusion of fluid.
a device consisting of an inflatable cuff which is placed around an I.V. bag. When the device is inflated, it increases the pressure on the I.V. bag to assist the infusion of fluid.
I am sorry, but the provided text does not contain the information required to answer your request. The document is an FDA 510(k) clearance letter for a "MSI Pressure Infusor" device, dated October 29, 1997. It primarily confirms that the device is substantially equivalent to legally marketed predicate devices and outlines general regulatory obligations.
The document does not include any details about:
- Acceptance criteria for performance.
- A study proving the device meets acceptance criteria.
- Sample sizes for test or training sets.
- Data provenance.
- Number or qualifications of experts.
- Adjudication methods.
- MRMC comparative effectiveness studies or effect sizes.
- Standalone algorithm performance.
- Types of ground truth used.
- How ground truth for a training set was established.
This type of information is typically found in a detailed device submission, clinical study report, or a summary of safety and effectiveness, which are not part of this clearance letter.
Ask a specific question about this device
Page 1 of 1